Abstract
Methods Analyses were performed upon Reuma.pt. Response to therapy was defined according to EULAR criteria. Probability of response was modeled. Multivariate logistic regression model predicting response over 1 year with all variables and automated stepwise selection models were built. In addition, we performed analyses using propensity score 1:1:1 nearest neighbor matching algorithms to obtain comparable groups regarding baseline features.
Highlights
Tumor necrosis factor (TNF) antagonist therapies changed the rheumatoid arthritis treatment paradigm but arguments to choose among anti-TNF are lacking
The aim of this work was to evaluate the comparative effectiveness of adalimumab, etanercept and infliximab over 1 year in clinical practice
No significant differences in treatment response were detected after applying the matching propensity score analysis
Summary
Helena Canhão*, Ana F Mourão, Fernando Martins, Maria J Santos, Canas Silva, Joaquim Pereira, JA Pereira Silva, José Costa, Domingos Araujo, Candida Silva, Eugenia Simões, Catia Duarte, José Antonio P Silva, Fernando Pimentel, Jaime Branco, João E Fonseca. From 6th European Workshop on Immune-Mediated Inflammatory Diseases Nice, France. From 6th European Workshop on Immune-Mediated Inflammatory Diseases Nice, France. 23-25 November 2011
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
